- Home
- NAK vs MGNX Comparison
NAK vs MGNX Comparison
Compare NAK & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAK
- MGNX
- Stock Information
- Founded
- NAK 1983
- MGNX 2000
- Country
- NAK Canada
- MGNX United States
- Employees
- NAK N/A
- MGNX N/A
- Industry
- NAK Precious Metals
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- NAK Basic Materials
- MGNX Health Care
- Exchange
- NAK Nasdaq
- MGNX Nasdaq
- Market Cap
- NAK 243.1M
- MGNX 257.3M
- IPO Year
- NAK 2002
- MGNX 2013
- Fundamental
- Price
- NAK $0.46
- MGNX $3.21
- Analyst Decision
- NAK Strong Buy
- MGNX Buy
- Analyst Count
- NAK 1
- MGNX 11
- Target Price
- NAK $1.30
- MGNX $8.57
- AVG Volume (30 Days)
- NAK 3.2M
- MGNX 753.5K
- Earning Date
- NAK 11-15-2024
- MGNX 11-05-2024
- Dividend Yield
- NAK N/A
- MGNX N/A
- EPS Growth
- NAK N/A
- MGNX N/A
- EPS
- NAK N/A
- MGNX N/A
- Revenue
- NAK N/A
- MGNX $141,329,000.00
- Revenue This Year
- NAK N/A
- MGNX $119.63
- Revenue Next Year
- NAK N/A
- MGNX N/A
- P/E Ratio
- NAK N/A
- MGNX N/A
- Revenue Growth
- NAK N/A
- MGNX 16.68
- 52 Week Low
- NAK $0.23
- MGNX $2.95
- 52 Week High
- NAK $0.56
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- NAK 55.22
- MGNX 36.82
- Support Level
- NAK $0.31
- MGNX $3.61
- Resistance Level
- NAK $0.51
- MGNX $5.10
- Average True Range (ATR)
- NAK 0.04
- MGNX 0.36
- MACD
- NAK -0.00
- MGNX -0.10
- Stochastic Oscillator
- NAK 41.29
- MGNX 2.58
About NAK Northern Dynasty Minerals Ltd.
Northern Dynasty Minerals Ltd is a Canadian mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a significant deposit of copper, gold, molybdenum, and silver into a modern mining operation.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).